Syncom Formulations (India) Ltd Share Price

Pharmaceuticals

NSE: SYNCOMF Small Cap ISIN: INE312C01025

As on 13 June 2026 at 02:17 IST

₹14.26

+ 0.35

(2.52%)

Sell Buy

Syncom Formulations (India) Q1 FY26 Results:

Profit for the period increased by 106.4% to ₹15.75 crores in Q1 FY26, from ₹7.63 crores in Q1 FY25. Total income for the quarter increased by 38.8% year-on-year to ₹122.93 crores from ₹88.59 crores.

About Syncom Formulations (India) Ltd

Syncom Formulations is an Indian company that makes medicines. It falls under the pharmaceutical sector. The company has been in business for many years since it was established in the year 1995. This makes it a well-established player in the Indian medicine market. Headquartered in the city of Mumbai, Maharashtra, the Bankda family holds a significant portion of shares in the company. Syncom primarily manufactures generic pharmaceutical products. Its main products include tablets, capsules, liquid medicines, and injectable drugs for various health conditions like pain relief, infections, and chronic diseases. +

Over 1 Month

-3.20%

Over 6 Months

-6.96%

Over 1 Year

-37.20%

Over 3 Years

80.65%

Syncom Formulations (India) Ltd Summary

Close ₹13.91

Open ₹14.13

High ₹14.13

Low ₹13.74

Volume 19,89,631

Net Turnover (in Cr) ₹2.78

52Wk High ₹22.64

52Wk Low ₹10.21

52Wk High / Low

10.21

22.64

Syncom Formulations (India) Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹1,307.54

EPS (TTM) 0.81

Book Value (BV) 4.39

Div. Yield -

P/E (TTM) 17.14

Price/Book Value 3.16

Delivery % 32.11 %

Face Value 1

Key Ratios

PE Ratio 31.63

PB Ratio 4.54

EV to Sales 3.35

PEG Ratio 0.29

ROA 13.98

ROE 15.60

Debt-Equity 0.12

Net Profit Margin 10.56

Operating Profit Margin 15.31

Syncom Formulations (India) Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017
Total Revenue	482.45	276.91	238.85	231.66	187.61
Total Expenses	416.94	242.94	212.29	205.50	171.73
Profit Before Tax	65.51	33.95	26.57	26.18	15.88
Profit After Tax	49.43	25.31	20.07	19.79	10.53
Operating Profit After Depreciation	66.37	38.45	29.69	28.08	16.17

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017
Fixed Assets	77.57	72.42	43.40	46.61	55.04
Total Non Current Assets	143.31	129.88	196.14	168.44	97.38
Total Current Assets	269.97	274.78	181.69	139.80	82.79
Total Assets	413.28	404.66	377.83	308.24	180.17
Total Shareholder's Fund	342.16	288.14	256.01	222.22	117.35

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017
Net Cash From Operating Activities	23.44	-5.96	10.53	16.33	13.84
Net Cash Used In Investing Activities	-18.20	83.02	-44.95	-27.07	-17.68
Net Cash Used In Financing Activities	-67.90	-14.56	35	8.29	4.67

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	480.04	271.46	239.25	231.66	251.95
Total Expenses	415.39	239.68	212.70	205.50	211.27
Profit Before Tax	64.66	31.76	26.57	26.18	40.70
Profit After Tax	48.87	23.62	20.07	19.79	29.17
Operating Profit After Depreciation	65.50	36.23	29.68	28.08	41.03

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	77.57	72.42	43.40	46.61	44.32
Total Non Current Assets	142.22	128.86	196.17	168.44	101.81
Total Current Assets	267.46	262.64	180.77	139.80	189.84
Total Assets	409.69	391.50	376.94	308.24	291.65
Total Shareholder's Fund	339.90	286.45	256.01	222.22	187.58

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	23.31	-5.94	10.50	16.33	-2.06
Net Cash Used In Investing Activities	-18.38	83.83	-44.97	-27.07	-75.35
Net Cash Used In Financing Activities	-67.59	-15.37	35	8.29	71.96

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	135.41	115.14	121.72	116.90	148.88
Total Expenses	113.40	93.93	103.32	101.09	131.12
Profit Before Tax	33.70	25.09	22.04	20.29	23.30
Profit After Tax	25.17	18.91	16.60	15.75	17.69
Operating Profit after Depreciation	36.56	26.71	23.65	21.84	24.70

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	134	114.59	121.44	116.55	148.46
Total Expenses	112.52	93.42	102.71	100.77	130.99
Profit Before Tax	32.86	25.04	22.36	20.26	23
Profit After Tax	24.57	18.86	16.84	15.73	17.50
Operating Profit after Depreciation	35.71	26.65	23.96	21.80	24.37

Syncom Formulations (India) Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 13.72

S2 13.54

S3 13.33

Pivot 13.93

R1 14.11

R2 14.32

R3 14.50

Moving Average

20 SMA 14.55

50 SMA 13.82

100 SMA 13.27

200 SMA 14.68

Syncom Formulations (India) Ltd Corporate Actions

Syncom Formulations (India) Ltd

₹0.03/Share

Announcement Date 09 Sep 2022

Record Date 13 Sep 2022

Div Yield 3%

AGM Date: 27 Sep 2021

AGM 27/09/2021 Pursuant to the Regulation 30(2) read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015 we are pleased to submit the proceedings of the 33rd Annual General Meeting of Syncom Formulations (India) Limited duly held on Monday,27th September, 2021 at 2:00 P.M. (IST) and concluded at 2:28 P.M. (IST) through Video Conferencing or Other Audio Video Means (OAVM) for which purposes the Registered office of the company situated at 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East) Mumbai - 400 093 (M.H.) shall be deemed as the venue for the Meeting. Please note that the results of e-voting will be intimated to you separately upon receipt of Report from the Scrutinizer within 2 Working days from the conclusion of the Annual General Meeting. You are requested to please take on record the above said document for your reference and further needful. (As per BSE Announcement Dated on 27/09/2021) we hereby submit the results of (remote e-voting and E-voting at AGM) of 33rd Annual General Meeting of the Company held on Monday 27th September 2021 at 2:00 P.M. (IST) and concluded at 2:28 P.M. (IST) through Video Conferencing and Other Audio Visual Means (OAVM). Kindly note that the Chairman has declared the result of voting of the aforesaid Annual General Meeting on 29th September 2021 on the basis of report submitted by the Scrutinizer for remote e-voting and E-voting at AGM for the above mentioned purpose. We are in the process of filing the aforesaid results in XBRL mode. We are also enclosing the Scrutinizers Report and request you to please take the same on your records for reference and further needful. We are pleased to inform that the members of the Company has considered and approved the following resolutions which were put before them on 33rd Annual General Meeting which was held through VC/OAVM held on Monday the 27th September 2021 at 2:00 P.M. and concluded at 2.28 P.M. (As Per BSE Announcement Dated on 9/29/2021 6:23:52 AM) With reference to the Regulation 30 read with Schedule III of SEBI (LODR) Regulation 2015 we hereby submit the detailed Proceedings/Minutes of the 33rd Annual General Meeting of Company held on Monday. 27th September 2021 at 2:00 P.M. (1ST) and concluded at 2:28 P.M. (1ST) through Video Conferencing (VC)/Other Audio Visual Means (OAVM) for which purpose the Registered Office situated at 7 Niraj Industrial Estate Off Mahakali Caves Road Andheri (East) Mumbai (M.H.) 400 093 shall be deemed as the Venue for the meeting.(As Per BSE Announcement Dated on 10/18/2021 7:20:51 AM)

AGM Date: 19 Sep 2022

AGM 19/09/2022 Outcome of the 5/2022-23 Meeting of the Board of Directors of the Company held on Saturday, 13th August, 2022 at 207, Saket Nagar, Near Saket Club, Indore (M.P.) 452018 at 4:00 P.M. as per Regulation 30 read with Schedule III(A)(IV) of the SEBI(LODR) Regulations, 2015. We are pleased to inform you that pursuant to the provisions of Regulation 42 of SEBI (LODR) Regulations, 2015 read with the provisions of section 91 of the Companies Act, 2013 the Register of Members and Share transfer books of the Company shall remain closed from Tuesday, 13thSeptember, 2022 to Monday, 19th September, 2022 (both days inclusive) for the purpose of the ensuing 34thAnnual General Meeting of the Company to be held on Monday, 19th September, 2022, through Video Conferencing / Other Audio Visual Means (VC)/(OAVM) and ascertain the entitlement for payment of dividend @ Rs.0.03/- (3%) per equity share of Rs.1/- each for the year 2021-22, if any, subject to approval by the members at their above said Annual General Meeting. We hereby submit the following information''s for the investors/ members of the Company:- Sr.No. Heading Particulars 1 Name of the Agency providing E-voting platform CDSL 2 Name of the Agency providing E-voting facility at AGM and VC/OAVM platform CDSL 3 Cut-off date for E-voting entitlement 12.09.2022 4 Voting Start Date & Time 16.09.2022 at 9:00 A.M. (IST) 5 Voting End Date & Time 18.09.2022 at 5:00 P.M. (IST) 6 Name of the Scrutinizers CS Anish Gupta Practicing Company Secretary We are pleased to submit a copy of the Notice of the 34th Annual General Meeting of the Company to be held on Monday, the 19th day of September, 2022 at 2:00 P.M. through Video Conferencing (VC)/Other Audio Visual Means (OAVM) for which purpose the Registered Office of the Company situated at 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East) Mumbai (M.H.) 400093 shall be deemed as the venue for the meeting and the proceedings of the AGM shall be deemed to be made thereat. You are requested to please take on record the above said document for your reference and further needful. This is in continuation of our letter no. SYNCOM/SE/2022-23 dated 13th August, 2022 regarding Submission of the 34th AGM Notice for the Year ended 31st March, 2022. We hereby inform that due to Typographical error in the Item No. 6 along with the Explanatory Statement of the same in the said Notice, in the Item No.6 the Word an Ordinary Resolution shall be read as a Special Resolution and in the Explanatory Statement for Item No. 6 to be read as a Special Resolution where ever it appears.. Copy of revised 34th AGM Notice for the Year ended 31st March, 2022 is enclosed for your reference, and ignore the previous AGM Notice. You are requested to take on record and upload at the portal of BSE for your reference and record. (As Per BSE Announcement Dated on 18.08.2022) Please find enclosed herewith copy of the Newspaper Clippings of Notice of 34th Annual General Meeting (AGM), Remote E-voting and Book Closure and other details as published in 'Navshakti Maratha' (Mumbai Edition Local in Marathi) & 'Free Press' (Mumbai English Edition) on Tuesday, 30th August, 2022. You are requested to please take on record the above said documents for your reference and further needful. (As Per BSE Announcement Dated on 30/08/2022) Pursuant to the Regulation 30(2) read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015 we are pleased to submit the proceedings of the 34th Annual General Meeting of Syncom Formulations (India) Limited duly held on Monday,19th September, 2022 at 2:00 P.M. (IST) and concluded at 2:52 P.M. (IST) through Video Conferencing or Other Audio Video Means (VC/OAVM) for which purposes the Registered office of the company situated at 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East) Mumbai- 400 093 (M.H.) shall be deemed as the venue for the Meeting. Please note that the results of e-voting will be intimated to you separately upon receipt of Report from the Scrutinizer within two Working days from the conclusion of the Annual General Meeting. (As Per BSE Announcement Dated on 20.09.2022) With reference to the captioned subject, we hereby submit the results of (remote e-voting and E-voting at AGM) of 34th Annual General Meeting of the Company held on Monday, 19th September, 2022 at 2:00 P.M. (IST) and concluded at 2:52 P.M. (IST) through Video Conferencing and Other Audio Visual Means (VC/OAVM). Kindly note that the Chairman has declared the result of voting of the aforesaid Annual General Meeting on 21st September, 2022 on the basis of report submitted by the Scrutinizer for remote e-voting and e-voting at AGM for the above mentioned purpose. We are in the process of filing the aforesaid results in XBRL mode. We are also enclosing the Scrutinizer's Report and request you to please take the same on your records for reference and further needful. Corporate Announcement for approval of Final Dividend Rs. 0.03 (3.00%) on the 94,00,00,000 Equity Shares of Rs.1/- each of the Company by the Members for the year 2021-22 and dispatch of the Dividend Warrants/DDs. Declaration of Results of Remote E-voting and E-voting at Annual General Meeting, in compliance with Regulation 44(3) of SEBI (LODR) Regulation, 2015 in relation to the 34th Annual General Meeting of the Company held on 19th September, 2022 Outcome of the 34th Annual General Meeting of the Company held on Monday, 19th September, 2022 (As Per BSE Announcement Dated on 21.09.2022)

AGM Date: 26 Sep 2023

AGM 26/09/2023 Notice of 35th AGM of the Company to be held on Tuesday 26th September, 2023 at 3:00 P.M through VC/OAVM. (As Per BSE Announcement Dated on 29/08/2023) Pursuant to provisions of regulation 34(1) of the SEBI (LODR) Regulations, 2015, we are pleased to submit the 35thAnnual Report for the year 2022-23 of the Company containing the Balance Sheet as at 31st March, 2023, Statement of Changes in Equity and the Statement of the Profit and Loss and Cash Flow for the year ended 31st March, 2023 and the Boards' Report along with Corporate Governance Report, Business Responsibility And Sustainability Report (BRSR) and the Auditors' Report on that date and its annexures. Kindly note that the 35th Annual General Meeting of the Company is scheduled to be held on Tuesday, 26th September, 2023 at 3:00 P.M. through Video Conferencing ('VC')/ Other Audio Visual Means ('OAVM'). The above-mentioned documents are available on the Company's website at www.sfil.in (As Per BSE Announcement Dated on 04/09/2023) Proceedings of 35th Annual General Meeting of the Company (As Per BSE Announcement Dated on 26/09/2023) Outcome of the 35th Annual General Meeting (As per BSE Announcement Dated on 28/09/2023) Submission of Minutes of Annual General Meeting held on 26.09.2023 (As per BSE Announcement Dated on 26/10/2023)

AGM Date: 30 Sep 2024

AGM 30/09/2024 We hereby submit the Voting Results of the 36th Annual General Meeting held on 30.09.2024 alongwith the Scrutiniser Report submitted to the company on 03.10.2024. (As Per BSE Announcement dated on 03.10.2024) Submission of the Minutes of the 36th Annual General Meeting held on 30th September, 2024 (As per BSE Announcement Dated on 17/10/2024)

AGM Date: 29 Sep 2025

AGM 29/09/2025 Pursuant to Reg 44, SEBI LODR, 2015, EVOTING FACILITY FOR 37TH AGM TO BE HELD ON 29TH SEPTEMBER, 2025 Pursuant to Reg 42 of SEBI(LODR), 2015, THE REGISTER OF MEMBERS AND SHARE TRANSFER WILL BE CLOSED FROM 23RD SEPTEMBER, 2025 TO 29TH SEPTEMBER, 2025 (As Per BSE Announcement Dated on: 08.08.2025) Proceedings of 37th Annual General Meeting held on 29th September, 2025 (As Per BSE Announcement Dated on 29.09.2025) Submission of Results for the 37th Annual general meeting held on 29th Sep, 2025 Outcome of 37th Annual General meeting held on 29th Sep, 2025 (As per BSE Announcement dated on: 01.10.2025)

Syncom Formulations (India) Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,794.30	₹4,30,512.67
Divis Laboratories Ltd	₹6,651.25	₹1,76,569.79
Torrent Pharmaceuticals Ltd	₹4,570	₹1,54,669.57
Cipla Ltd	₹1,383	₹1,11,725.01
Zydus Lifesciences Ltd	₹1,105.65	₹1,11,254.26

Syncom Formulations (India) Ltd Top Mutal Funds Invested

Fund Name	AUM
Bandhan BSE Healthcare Index Fund	0.05%

Syncom Formulations (India) Ltd News

Syncom Formulations (India) schedules board meeting

On 22 May 2026

14 May 2026, 10:40 am

Syncom Formulations (India) to convene board meeting

On 12 February 2026

04 Feb 2026, 04:03 pm

Syncom Formulations (India) announces board meeting date

On 12 November 2025

08 Nov 2025, 12:37 pm

Syncom Formulations (India) schedules AGM

On 29 September 2025

12 Aug 2025, 12:18 pm

Syncom Formulations (India) to table results

On 8 August 2025

04 Aug 2025, 11:23 am

Syncom Formulations (India) Ltd Stock Analysis

Annual revenue for Syncom Formulations (India) Ltd increased by 76.84% to ₹480.04 crore in FY 2025 from ₹271.46 crore in FY 2024.
Annual Net Profit for Syncom Formulations (India) Ltd increased by 106.88% to ₹48.87 crore in FY 2025 from ₹23.62 crore in FY 2024.
Promoter Shareholding in Syncom Formulations (India) Ltd remains unchanged by 0.00% in the most recent quarter, from 50.57% in December 2025 to 50.57% in March 2026.
Syncom Formulations (India) Ltd delivered a 1-year return of -37.20% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
Syncom Formulations (India) Ltd share price moved up by 2.52% from its previous close of INR ₹13.91. The latest Syncom Formulations (India) Ltd share price is INR ₹14.26.
Syncom Formulations (India) Ltd share price today has been at a low of 14 and a high of 14.29. Over the past 52 weeks, the Syncom Formulations (India) Ltd share price has seen a low of 10.21 and a high of 22.64.

About Syncom Formulations (India) Ltd

Syncom Formulations is an Indian company that makes medicines. It falls under the pharmaceutical sector, which means it creates and sells drugs to help people get better when they're sick. The company has been in business for many years since it was established in 1995. This makes it a well-established player in the Indian medicine market.
Syncom primarily manufactures generic pharmaceutical products. Its main products include tablets, capsules, liquid medicines, and injectable drugs for various health conditions like pain relief, infections, and chronic diseases. While Syncom Formulations is known in the Indian pharmaceutical industry, it is not the #1 player in the sector. The Indian pharmaceutical market has many bigger companies with larger market shares.
Headquartered in Mumbai, Maharashtra, the Bankda family holds a significant portion of shares in the company, showing their strong commitment to the business. Kedarmal Shankarlal Bankda serves as Executive Chairman. Apart from him, there are many other managerial promoters who have contributed to the success of the company. They are –

Vijay Shankarlal Bankda
Rinki Ankit Bankda
Ruchi Jindal
Ritesh Kumar Lunkad

The registered office of Syncom is located at 7 Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East). Meanwhile, the registrars are based at 60 Electronic Complex, Pardeshipura, Indore 452010, and handle the company's share-related matters. Overall, as a mid-sized pharmaceutical manufacturer, Syncom continues to serve the healthcare needs of people while competing in India's growing medicine market.

The Impact of Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd has made a significant impact on the Indian pharmaceutical landscape. This company has been working for nearly four decades to provide affordable medicines to people. They focus on making generic drugs that help treat various health conditions.
The company was founded in 1983 and has grown steadily since then. They started small but now have expanded over time. Today, they have their registered office in Mumbai at Niraj Industrial Estate, Off Mahakali Caves Road in Andheri East. This strategic location helps them connect with the financial hub of India.
The Bankda family has been at the heart of Syncom's story from the beginning. They are the main promoters of the company. Kedarmal Shankarlal Bankda serves as the Executive Chairman. He provides leadership and vision to the company. Vijay Shankarlal Bankda works as the Managing Director. He handles the day-to-day operations of the business.
The company's registrar is located in Indore at Electronic Complex, Pardeshipura. This office handles all share-related matters for the company. It manages shareholder records and processes dividend payments.
Their medicines treat a wide range of health conditions. Some help with pain relief, while others fight infections. The company also manufactures medicines for chronic diseases like diabetes and high blood pressure. As a result, by making these medicines affordable, Syncom has helped many people access affordable healthcare.
The pharmaceutical sector in India is very competitive. It has many players of different sizes. While Syncom is not the biggest company in this sector, it has carved out its own space by focusing on quality and affordability.
Over the years, Syncom has adapted to changing market conditions. The pharmaceutical industry faces many regulations. These rules are designed to ensure drug safety and effectiveness. Plus, Syncom has also worked tirelessly to comply with these regulations while staying competitive.
The company employs many people across its operations. These include scientists, production workers, quality control experts, and sales professionals. By creating these jobs, Syncom contributes to the Indian economy. This also helps with developing skilled pharmaceutical professionals.
The company faces challenges, too. The pharmaceutical market is highly regulated. New rules can add costs and complexity to operations. Competition is intense, with many companies making similar products. Raw material costs can fluctuate, affecting profit margins.
Despite these challenges, Syncom has maintained its presence in the market. They continue to produce medicines that people need. On top of that, their longevity speaks to their resilience and business approach.
The pharmaceutical industry serves a critical human need – health. Companies like Syncom play a vital role in the healthcare ecosystem. They produce the medicines that doctors prescribe. Their medicines help people recover from illness and manage chronic conditions.
Corporate governance matters in pharmaceutical companies. Syncom's board includes independent directors who provide oversight. This structure helps ensure that the company operates ethically. It also protects the interests of all shareholders.
The future holds both opportunities and challenges for companies like Syncom. As India's population grows and ages, the need for medicines will increase. Healthcare awareness is also rising, with more people seeking treatment for conditions that were previously ignored.
At the same time, competition continues to intensify. Larger companies have advantages of scale, while smaller companies may be more nimble. So, Syncom is working hard to find ways to leverage its strengths while overcoming limitations. Their four decades of experience will be valuable in navigating these challenges.